Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis

Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis

Imatinib mesilate is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients ar...

Full description

Bibliographic Details
Main Authors: I. N. Mikhaylova, N. M. Treshalina, I. Zh. Shubina, I. V. Manina, M. V. Kiselevsky, A. N. Lukashev
Format: Article
Language:Russian
Published: ABV-press 2021-01-01
Series:Успехи молекулярной онкологии
Subjects:
antitumor drug
imatinib mesylate
tyrosine protein kinase
pneumofibrosis
covid-19
Online Access:https://umo.abvpress.ru/jour/article/view/300

Similar Items

Similar Items